Thomas Gobbetti Email and Phone Number
PhD and +12 years’ experience in the field of experimental pharmacology, inflammation and immunology both in academia and pharmaceutical industry.I obtained my PhD in Experimental Pharmacology and Toxicology from the University of Parma in 2011. I continued my scientific interests as an academic post-doctoral fellow for six years at INSERM in Toulouse and the William Harvey Research Institute at Queen Mary University.My time at these world-renowned research Institutions kindled my interest in how scientific discoveries can translate into meaningful patient benefit and prompted me to join a leading pharmaceutical company such as GSK in 2017 and the University College London spin-off Engitix in 2022.My experience in the industry setting gave me a wide knowledge of the drug discovery process (strong background in inflammatory/autoimmune diseases and fibrosis) from supporting the identification and validation of new targets to late stage clinical development of small molecules and biologics approaches.At Engitix, with a first-in-class platform aimed at deconvoluting the bioactive role of the tissue-specific and disease-specific acellular microenvironment, we aim to generate new and more relevant therapeutics against fibrosis and solid tumors, and meaningful biomarkers to ensure their delivery to the right patients. By combining our unique understanding of the ECM with world-class technology, including a unique tissue collection, proprietary tissue decellularization protocols, and Engitomix bioinformatic software, Engitix is unlocking insights and developing physiologically realistic in vitro three-dimensional (3D) platforms incorporating the ECM. Key strengths:• PhD in Experimental Pharmacology and Toxicology• Immunology and Inflammation and fibrosis in academia and industry setting• Strong project management, planning and leadership skills• Excellent communication skills, written and oral presentation to variety of audience• Proven ability to publish peer-reviewed manuscripts and extract key scientific data from published literature• Extensive laboratory skills in in vivo but also cellular biology, data collection and analysis• Very good team player, mentoring and teaching skills with highly educated team• Strong critical thinking and problem solving skills• Ability to operate under pressure and deliver to demanding deadlines
Forcefield Therapeutics
View- Website:
- forcefieldtx.com
- Employees:
- 8
-
Director Of Translational PharmacologyForcefield TherapeuticsLondon, Gb -
Liver Fibrosis Progamme Leader And Director Of Translational Biology / In VivoEngitix Therapeutics Sep 2022 - PresentLondon, England, United KingdomAt Engitix, with a first-in-class platform aimed at deconvoluting the bioactive role of the tissue-specific and disease-specific acellular microenvironment we aim to generate new and more relevant therapeutics against fibrosis and solid tumors, and meaningful biomarkers to ensure their delivery to the right patients. By combining our unique understanding of the ECM with world-class technology—including a unique tissue collection, proprietary tissue decellularization protocols, and Engitomix bioinformatic software—Engitix is unlocking insights and developing physiologically realistic in vitro three-dimensional (3D) platforms incorporating the ECM. -
Scientific LeaderGsk Feb 2018 - Sep 2022Stevenage, United KingdomHighly motivated translational team leader within the Quantitative Pharmacology Group at GSK. Lead in the design and implementation of pre-clinical model strategies to support progression of novel therapies in the immune-inflammation therapeutic area portfolio. The Experimental Quantitative Pharmacology group is a multidisciplinary team of scientists with expertise in immunologically relevant PKPD and disease aligned animal models (working in close proximity with DMPK). My role is to design pre-clinical strategy to establish translational biology and PKPD relationships providing a package enabling molecule selection, human dose predictions, and forms the basis of experimental medicine studies. My focus in the group is to strengthen the translational platform and develop translatable models to better predict clinical efficacy, including the translation of animal model data to support pre-clinical bio-marker strategies, and subsequently reduce attrition during late stage development. -
Translational Scientist/VeterinarianGsk Feb 2017 - Jan 2018Stevenage, United KingdomMy role is to provide scientific support to program and project teams for the utilization of animal models in drug discovery and development, and provide expertise in comparative biology, translational science, and the development of human disease relevant models, including complex in vitro models. Accountable for proactive scientific dialogue with teams across R&D and external partners; contributing to team discussions which impact animal and non-animal model development, validation/relevance, use, interpretation and reporting. Assist with scientific and technological exchange with internal and external partners, facilitating the smooth transfer of information and advice to accomplish scientific objectives. -
Postdoctoral ResearcherQueen Mary University Of London Apr 2012 - Jan 2017William Harvery Research Institute - London, United KingdomFunded by the Welcome Trust and William Harvey Research FoundationMy experimental activities have always evolved around the area of cardiovascular inflammation. Investigation into the modulatory properties of FPR2/ALX, a G protein-coupled receptor belonging to the formyl peptide receptor (FPR) family, specifically investigating sepsis, myocardial ischemia and skeletal muscle regeneration. More recently, this has focussed on novel n-3 metabolites and their role in promoting the resolution of inflammation impacting on leukocytes and epithelial cells following intestinal ischemia reperfusion and colitis.Full understanding of in vivo and in vitro experimental work from the design of the experiments to the analysis and interpretation of the results in order to test the efficacy and the mechanisms of action of selected drugs (experience with animal models of disease [in mouse, rat, and guinea pig] of translational relevance). -
Postdoctoral ResearcherInserm Apr 2011 - Mar 2012Inserm Toulouse, FranceFunded by National Funding Agency for Research – ANRInvestigating how polyunsaturated fatty acids (PUFAs) metabolites signature in intestinal ischemia differs from reperfusion using high sensitivity liquid chromatography tandem mass spectrometry. In particular, studying how dietary fatty acid (n-3 versus n-6) intake determines the outcome of intestinal/reperfusion-induced damage in the gut. -
Research Fellowship As Temporary Research AssociateUniversity Of Parma Oct 2007 - Sep 2011Parma Area, ItalyThis fellowship financed my PhD. Research Theme: “Pathophysiology of serine proteinases and Protease-activated Receptors in intestinal ischemia-reperfusion injury”.Winner of European Commission’s Lifelong Learning Programme (LLP) scholarship, from April 2009 I performed my research activities in Toulouse (France) as PhD visiting student.Genuinely committed to study the proteolytic profile associated with inflammation, investigating the correlation between proteases and their receptors specifically in the context of intestinal vascular inflammation. -
Animal Care Facility OperatorUniversity Of Parma Oct 2006 - Oct 2007Helping Animal Care Facility Manager oversee animal health including routine medical procedures or the administration of euthanasia on impounded animals. Additionally, I oversaw the maintenance of Animal Care Facility records and statistics. -
Training StudentUniversity Of Parma 2005 - 2007Parma Area, ItalyTraining Student, Laboratory of Pharmacology and Toxicology Faculty of Veterinary Medicine University of Parma, Italy. Research Theme: “Role of cyclooxygenases in the equine small intestine”.
Thomas Gobbetti Skills
Thomas Gobbetti Education Details
-
Inflammation -
Universita Degli Studi Di ParmaBachelor Of Veterinary Science
Frequently Asked Questions about Thomas Gobbetti
What company does Thomas Gobbetti work for?
Thomas Gobbetti works for Forcefield Therapeutics
What is Thomas Gobbetti's role at the current company?
Thomas Gobbetti's current role is Director of Translational Pharmacology.
What schools did Thomas Gobbetti attend?
Thomas Gobbetti attended Queen Mary University Of London, Università Degli Studi Di Parma, Universita Degli Studi Di Parma.
What are some of Thomas Gobbetti's interests?
Thomas Gobbetti has interest in Animal Welfare, Education, Science And Technology, Health.
What skills is Thomas Gobbetti known for?
Thomas Gobbetti has skills like Cell Biology, Cell Culture, Western Blotting, Biochemistry, Fluorescence Microscopy, Qpcr, Immunohistochemistry, Flow Cytometry, Cell, Pcr, In Vivo, Veterinary Medicine.
Not the Thomas Gobbetti you were looking for?
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial